{"protocolSection": {"identificationModule": {"nctId": "NCT02192814", "orgStudyIdInfo": {"id": "EP0024"}, "secondaryIdInfos": [{"id": "EP0024", "type": "OTHER", "domain": "JAPIC"}], "organization": {"fullName": "UCB Pharma", "class": "INDUSTRY"}, "briefTitle": "Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures", "officialTitle": "A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Secondary Generalization"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-06"}, "primaryCompletionDateStruct": {"date": "2014-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-07-11", "studyFirstSubmitQcDate": "2014-07-15", "studyFirstPostDateStruct": {"date": "2014-07-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-30", "resultsFirstSubmitQcDate": "2015-10-30", "resultsFirstPostDateStruct": {"date": "2015-12-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-07-28", "lastUpdatePostDateStruct": {"date": "2017-08-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UCB Japan Co. Ltd.", "class": "INDUSTRY"}, "collaborators": [{"name": "Parexel", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM). Adjunctive iv LCM therapy (200 mg/day to 400 mg/day) will be administered for 5 days as replacement for oral LCM tablets in Japanese adults with partial-onset seizures."}, "conditionsModule": {"conditions": ["Epilepsy", "Partial-onset Seizures"], "keywords": ["Lacosamide", "LCM", "Epilepsy", "Partial-onset seizures", "iv"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 9, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lacosamide (LCM)", "type": "EXPERIMENTAL", "description": "On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day).", "interventionNames": ["Drug: Lacosamide (200 mg/20 mL)"]}], "interventions": [{"type": "DRUG", "name": "Lacosamide (200 mg/20 mL)", "description": "Active Substance: Lacosamide\n\nPharmaceutical form: Solution for intravenous (iv) infusion\n\nConcentration: adapted on concentration of oral dose in EP0009\n\nRoute of Administration: Drip infusion", "armGroupLabels": ["Lacosamide (LCM)"], "otherNames": ["Vimpat"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Total Number of Subjects Experiencing at Least One Adverse Event During the Study", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "timeFrame": "During the study (Screening through End of Study (Day -1 through Day 6))"}, {"measure": "The Total Number of Subject Withdrawal Due to Adverse Events During the Study", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "timeFrame": "During the study (Screening through End of Study (Day -1 through Day 6))"}], "secondaryOutcomes": [{"measure": "Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 1", "timeFrame": "20 minutes prior infusion at Day 1"}, {"measure": "Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 2", "timeFrame": "20 minutes prior infusion at Day 2"}, {"measure": "Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 5", "timeFrame": "20 minutes prior infusion at Day 5"}, {"measure": "Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 1", "timeFrame": "20 minutes prior infusion at Day 1"}, {"measure": "Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 2", "timeFrame": "20 minutes prior infusion at Day 2"}, {"measure": "Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 5", "timeFrame": "20 minutes prior infusion at Day 5"}], "otherOutcomes": [{"measure": "The Cumulative Partial-onset Seizure Frequency From Day -1 to Day 5", "description": "No descriptive statistics have been calculated for this exploratory Outcome Measure.", "timeFrame": "From Day -1 to Day 5"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subject is Japanese and enrolled in EP0009 (NCT01832038) receiving oral Lacosamide (LCM) for the treatment of partial-onset seizures and has been enrolled for at least 8 weeks\n* Subject has been on a stable twice daily (bid) dosage regimen of LCM 200 mg/ day to 400 mg/ day, for the 2 weeks prior to entry into EP0024\n* Subject has been receiving no more than 3 concomitant Antiepileptic Drugs (AEDs) at doses that have remained stable for the 2 weeks prior to entry into EP0024\n\nExclusion Criteria:\n\n* Subject has a history of any kind of status epilepticus within 12-month period prior to study entry\n* Subject has actual suicidal ideation as indicated by a positive response (\"Yes\") to either Question 4 or Question 5 of the \"Since Last Visit\" version of the Columbia-Suicide Severity Rating Scale (C-SSRS)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "UCB Clinical Trial Call Center", "affiliation": "1-877-822-9493", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "81027", "city": "Hamamatsu", "country": "Japan", "geoPoint": {"lat": 34.7, "lon": 137.73333}}, {"facility": "81024", "city": "Kodaira", "country": "Japan"}, {"facility": "81025", "city": "Sapporo", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "81003", "city": "Shizuoka", "country": "Japan", "geoPoint": {"lat": 34.98333, "lon": 138.38333}}, {"facility": "81023", "city": "Suita", "country": "Japan", "geoPoint": {"lat": 34.76143, "lon": 135.51567}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "FDA Safety Alerts and Recalls", "url": "http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participant Flow refers to the Safety Set (SS), consisting of all enrolled subjects who received at least 1 infusion of iv LCM.", "recruitmentDetails": "This multicenter, open-label study started recruiting in June 2014.", "groups": [{"id": "FG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Participant Flow refers to the Safety Set (SS), consisting of all enrolled subjects who received at least 1 infusion of iv LCM.\n\nSubjects participating in EP0009 (NCT01832038) have been enrolled to EP0024.", "groups": [{"id": "BG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.9", "spread": "10.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.99", "spread": "13.13"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "centimeter (cm)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "159.07", "spread": "8.63"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Total Number of Subjects Experiencing at Least One Adverse Event During the Study", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "During the study (Screening through End of Study (Day -1 through Day 6))", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}]}, {"type": "PRIMARY", "title": "The Total Number of Subject Withdrawal Due to Adverse Events During the Study", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "During the study (Screening through End of Study (Day -1 through Day 6))", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 1", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "20 minutes prior infusion at Day 1", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.738", "spread": "50.5"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 2", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "20 minutes prior infusion at Day 2", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.004", "spread": "55.4"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 5", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "20 minutes prior infusion at Day 5", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.615", "spread": "60.0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 1", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "20 minutes prior infusion at Day 1", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.838", "spread": "46.6"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 2", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "20 minutes prior infusion at Day 2", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.330", "spread": "50.0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 5", "populationDescription": "The Safety Set (SS) consisted of all enrolled subjects who received at least 1 infusion of iv LCM.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "20 minutes prior infusion at Day 5", "groups": [{"id": "OG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.621", "spread": "38.8"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "The Cumulative Partial-onset Seizure Frequency From Day -1 to Day 5", "description": "No descriptive statistics have been calculated for this exploratory Outcome Measure.", "reportingStatus": "NOT_POSTED", "timeFrame": "From Day -1 to Day 5", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse Events (AEs) were collected from Screening Period (Day -1) until End-of-Study Period (Day 6).", "description": "Adverse Events refer to the Safety Set (SS) which constisted of all all enrolled subjects who received at least 1 infusion of iv LCM.", "eventGroups": [{"id": "EG000", "title": "Lacosamide (LCM)", "description": "On Day - 1, Lacosamide (LCM) oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.\n\nDuring the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.\n\nThe daily dose of iv LCM was be the same as the subject's current daily dose of oral LCM in EP0009 (200 - 400 mg/day).", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 4, "otherNumAtRisk": 9}], "otherEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Procedural headache", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "UCB Clinical Trial Call Center", "organization": "UCB Pharma", "phone": "+1877 822", "phoneExt": "9493"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}, {"id": "D000012640", "term": "Seizures"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M12307", "name": "Neoplasm Metastasis", "relevance": "LOW"}, {"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M15452", "name": "Seizures", "asFound": "Seizures", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000078334", "term": "Lacosamide"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000061567", "term": "Voltage-Gated Sodium Channel Blockers"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M1961", "name": "Lacosamide", "asFound": "Phase 3 Study", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}